Gene Therapy
Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.
131 stocks
| # | Name | Holding | Trade Value |
Theme Stocks |
% of Portfolio | Status | |
|---|---|---|---|---|---|---|---|
| 51 |
Perceptive Advisors
New York
| $351M | +$11.5M | 9 | 10.16% | Increased |
|
| 52 |
Allspring Global Investments
Charlotte,
North Carolina
| $348M | +$13.2M | 25 | 0.56% | Increased |
|
| 53 |
Nuveen
Charlotte,
North Carolina
| $336M | -$2.61M | 42 | 0.12% | Reduced |
|
| 54 |
Barclays
London,
United Kingdom
| $323M | +$119M | 59 | 0.2% | Increased |
|
| 55 |
Ameriprise
Minneapolis,
Minnesota
| $323M | +$11M | 29 | 0.1% | Increased |
|
| 56 |
Principal Financial Group
Des Moines,
Iowa
| $319M | -$32.3M | 33 | 0.22% | Reduced |
|
| 57 |
UBS Group
Zurich,
Switzerland
| $313M | +$10.9M | 88 | 0.11% | Increased |
|
| 58 |
Marshall Wace
London,
United Kingdom
| $308M | -$131M | 26 | 0.6% | Reduced |
|
| 59 |
First Trust Advisors
Wheaton,
Illinois
| $304M | -$18.3M | 13 | 0.35% | Reduced |
|
| 60 |
Fidelity International
Hamilton,
Bermuda
| $299M | +$96.8M | 5 | 0.34% | Increased |
|
| 61 |
Veritas Asset Management
London,
United Kingdom
| $294M | -$4.43M | 1 | 2.05% | Reduced |
|
| 62 |
EARNEST Partners
Atlanta,
Georgia
| $286M | +$5.48M | 5 | 1.6% | Increased |
|
| 63 |
Cullen Capital Management
New York
| $282M | -$66.4M | 1 | 2.52% | Reduced |
|
| 64 |
Lord, Abbett & Co
Jersey City,
New Jersey
| $275M | -$5.6M | 7 | 0.95% | Reduced |
|
| 65 |
Two Sigma Investments
New York
| $274M | +$31.2M | 50 | 0.69% | Increased |
|
| 66 |
BCM
Brown Capital Management
Baltimore,
Maryland
| $265M | -$2.45M | 2 | 3.75% | Reduced |
|
| 67 |
Farallon Capital Management
San Francisco,
California
| $254M | +$116M | 4 | 1.27% | Increased |
|
| 68 |
BBA
Baker Bros. Advisors
New York
| $252M | +$8.06M | 18 | 1.46% | Increased |
|
| 69 |
Two Sigma Advisers
New York
| $250M | -$49.8M | 36 | 0.64% | Reduced |
|
| 70 |
UBS O'Connor
Chicago,
Illinois
| $247M | +$207M | 13 | 5.21% | Increased |
|
| 71 |
Corvex Management
New York
| $246M | +$249M | 1 | 12.09% | New |
|
| 72 |
Paradigm Biocapital Advisors
New York
| $244M | +$78.9M | 4 | 18.83% | Increased |
|
| 73 |
Credit Suisse
Zurich,
Switzerland
| $239M | +$3.93M | 28 | 0.24% | Increased |
|
| 74 |
NMC
NEA Management Company
Timonium,
Maryland
| $237M | -$38.5M | 6 | 18.11% | Reduced |
|
| 75 |
Macquarie Group
Sydney, NSW 2000,
Australia
| $233M | -$19.2M | 20 | 0.27% | Reduced |
|